A Genetic Model for Gallbladder Carcinogenesis and Its Dissemination

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2014 Apr 8

PMID 24705974

Citations 31

Authors

S G Barreto

A Dutt

A Chaudhary

Affiliations

Soon will be listed here.

Abstract

Gallbladder cancer, although regarded as the most common malignancy of the biliary tract, continues to be associated with a dismal overall survival even in the present day. While complete surgical removal of the tumour offers a good chance of cure, only a fraction of the patients are amenable to curative surgery owing to their delayed presentation. Moreover, the current contribution of adjuvant therapies towards prolonging survival is marginal, at best. Thus, understanding the biology of the disease will not only enable a better appreciation of the pathways of progression but also facilitate the development of an accurate genetic model for gallbladder carcinogenesis and dissemination. This review provides an updated, evidence-based model of the pathways of carcinogenesis in gallbladder cancer and its dissemination. The model proposed could serve as the scaffolding for elucidation of the molecular mechanisms involved in gallbladder carcinogenesis. A better understanding of the pathways involved in gallbladder tumorigenesis will serve to identify patients at risk for the cancer (and who thus could be offered prophylactic cholecystectomy) as well as aid oncologists in planning the most suitable treatment for a particular patient, thereby setting us on the vanguard of transforming the current treatment paradigm for gallbladder cancer.

Citing Articles

Demographic and temporal variations in gallbladder adenocarcinoma and neuroendocrine carcinoma: insights from a retrospective analysis of the national cancer database.

Louis M, Ghosh A, Silin N, Dakkak T, Rynarzewska A, Cawthon M Cancer Causes Control. 2025; .

PMID: 39907908 DOI: 10.1007/s10552-025-01967-8.

EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.

Kim Y, Jee S, Kim H, Paik S, Choi D, Yoo S Oncologist. 2024; 29(8):e1051-e1060.

PMID: 38709907 PMC: 11299936. DOI: 10.1093/oncolo/oyae076.

Quantitative tissue proteome profile reveals neutrophil degranulation and remodeling of extracellular matrix proteins in early stage gallbladder cancer.

Akhtar J, Jain V, Kansal R, Priya R, Sakhuja P, Goyal S Front Oncol. 2023; 12:1046974.

PMID: 36686780 PMC: 9853450. DOI: 10.3389/fonc.2022.1046974.

Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.

Sturm N, Schuhbaur J, Huttner F, Perkhofer L, Ettrich T Cancers (Basel). 2022; 14(22).

PMID: 36428670 PMC: 9688543. DOI: 10.3390/cancers14225580.

Gallbladder cancer.

Roa J, Garcia P, Kapoor V, Maithel S, Javle M, Koshiol J Nat Rev Dis Primers. 2022; 8(1):69.

PMID: 36302789 DOI: 10.1038/s41572-022-00398-y.

References

Yoshida T, Sugai T, Habano W, Nakamura S, Uesugi N, Funato O . Microsatellite instability in gallbladder carcinoma: two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol. 2000; 35(10):768-74. DOI: 10.1007/s005350070036. View

Chang H, Kim S, Lee B, Hong E, Kim W . Phenotypic alterations of mucins and cytokeratins during gallbladder carcinogenesis. Pathol Int. 2004; 54(8):576-84. DOI: 10.1111/j.1440-1827.2004.01666.x. View

Feng Z, Chen J, Wei H, Gao P, Shi J, Zhang J . The risk factor of gallbladder cancer: hyperplasia of mucous epithelium caused by gallstones associates with p16/CyclinD1/CDK4 pathway. Exp Mol Pathol. 2011; 91(2):569-77. DOI: 10.1016/j.yexmp.2011.06.004. View

Saetta A, Lazaris A, Davaris P . Detection of ras oncogene point mutations and simultaneous proliferative fraction estimation in gallbladder cancer. Pathol Res Pract. 1996; 192(6):532-40. DOI: 10.1016/S0344-0338(96)80102-6. View

Le M, Henson D, Young H, Albores-Saavedra J . Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy?. Ann Hepatol. 2011; 10(3):306-14. View

Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Ishimaru S . Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol. 1996; 91(5):1007-11. View

Goldin R, Roa J . Gallbladder cancer: a morphological and molecular update. Histopathology. 2009; 55(2):218-29. DOI: 10.1111/j.1365-2559.2008.03192.x. View

Wistuba I, Gazdar A . Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004; 4(9):695-706. DOI: 10.1038/nrc1429. View

Cabibi D, Licata A, Barresi E, Craxi A, Aragona F . Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol Res Pract. 2003; 199(2):65-70. DOI: 10.1078/0344-0338-00356. View

10.

Wistuba I, Gazdar A, Roa I, Albores-Saavedra J . p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996; 27(4):360-5. DOI: 10.1016/s0046-8177(96)90109-4. View

11.

Wistuba I, Albores-Saavedra J . Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg. 1999; 6(3):237-44. DOI: 10.1007/s005340050113. View

12.

Finzi L, Barbu V, Burgel P, Mergey M, Kirkwood K, Wick E . MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am J Pathol. 2006; 169(6):2031-41. PMC: 1762466. DOI: 10.2353/ajpath.2006.060146. View

13.

Shukla P, Barreto S, Gupta P, Neve R, Ramadwar M, Deodhar K . Is there a role for estrogen and progesterone receptors in gall bladder cancer?. HPB (Oxford). 2008; 9(4):285-8. PMC: 2215398. DOI: 10.1080/13651820701481489. View

14.

Zou Q, Xiong L, Yang Z, Lv F, Yang L, Miao X . Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol. 2012; 10:92. PMC: 3433354. DOI: 10.1186/1477-7819-10-92. View

15.

Laitio M . Early carcinoma of the gallbladder. Beitr Pathol. 1976; 158(2):159-72. View

16.

Liu D, Yang Z . Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract. 2011; 207(8):472-8. DOI: 10.1016/j.prp.2011.05.010. View

17.

Shukla P, Neve R, Barreto S, Hawaldar R, Nadkarni M, Mohandas K . A new scoring system for gallbladder cancer (aiding treatment algorithm): an analysis of 335 patients. Ann Surg Oncol. 2008; 15(11):3132-7. DOI: 10.1245/s10434-008-9917-y. View

18.

Boonla C, Wongkham S, Sheehan J, Wongkham C, Bhudhisawasdi V, Tepsiri N . Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer. 2003; 98(7):1438-43. DOI: 10.1002/cncr.11652. View

19.

Kim Y, Huh S, Park Y, Yoon T, Lee S, Hong S . Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep. 2001; 8(5):1127-32. DOI: 10.3892/or.8.5.1127. View

20.

Kalekou H, Miliaras D . Cytokeratin 7 and 20 expression in gallbladder carcinoma. Pol J Pathol. 2011; 62(1):25-30. View